Document:

Exhibit
10.1

 

CONSENT
AND WAIVER AGREEMENT

 

This Consent and Waiver
Agreement (this “Agreement”) is made effective as of February 15, 2017 (the “Effective Date”)
by and among Sevion Therapeutics, Inc., a Delaware corporation (the “Company”),  the lead investor in the
2015 Financing (as defined below) (the “Lead Investor”), and the undersigned signatories hereto.

 

WHEREAS,
the Company is a party to those certain Subscription Agreements, dated as of May 1, 2015, May 29, 2015, June 10, 2015, June 24,
2015 and July 27, 2015, with the subscribers signatory thereto (each a “Subscriber” and together, the “Subscribers”),
including the Lead Investor (collectively referred to as the “Subscription Agreement”) whereby the Company issued
to each Subscriber (i) shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”)
or, at the election of the Subscriber, shares of the Company’s Series C Convertible Preferred Stock, par value $0.01 per
share (the “Series C Preferred Stock”) and (ii) a warrant to purchase one half of one share of the Company’s
Common Stock (the “Investor Warrants”) at an exercise price of $1.50 (the “Investor Warrant Exercise
Price”) (hereinafter referred to as the “2015 Financing”);

 

WHEREAS, pursuant
to that certain Engagement Agreement entered into by and between the Company and Laidlaw & Company (UK) Ltd., a United Kingdom
corporation (“Laidlaw”), as compensation for the services rendered by Laidlaw as placement agent for the 2015
Financing, the Company issued to Laidlaw, or its designees, warrants to purchase up to 555,521 shares of Common Stock (the “Placement
Agent Warrants”) at an exercise price of $0.75 (the “Placement Agent Warrant Exercise Price” and together
with the Investor Warrant Exercise Price, the “Exercise Price”);

 

WHEREAS, in connection
with the 2015 Financing, the Company entered into a registration rights agreement with each Subscriber in order to provide for
certain registration rights of the Subscriber’s shares of Common Stock issuable under the Warrants under the Securities Act
of 1933, as amended (the “Registration Rights Agreement”);

 

WHEREAS, the Company
intends to enter into a bridge financing transaction, as separately discussed with the Lead Investor, pursuant to which the Company
will issue and sell shares of its Common Stock or securities convertible into Common Stock to investors, at such price or conversion
price as reasonably determined by the Board (such transaction, a “Bridge Financing”);

 

WHEREAS,
Section 2(d) of the Subscription Agreement entitles the Subscribers, in connection with a Lower Price Issuance (as defined in the
Subscription Agreement) by the Company at any time prior to about January 27, 2017 (the “Expiration Date”),
to receive additional Units (as defined in the Subscription Agreement) such that the Subscriber shall hold such number of Units,
in total, had Subscriber paid a per Unit price equal to such Lower Price Issuance (hereinafter referred to as the “Price
Protection Provision”);

 

WHEREAS,
Section 3(e) of both the Investor Warrants and the Placement Agent Warrants entitles the holder thereof to have the Exercise Price
reduced, as applicable, upon the issuance by the Company, at any time prior to the Expiration Date, of shares of its Common Stock
for consideration less than the applicable Exercise Price (hereinafter collectively referred to as the “Adjustment of
the Exercise Price”);

 

WHEREAS, pursuant
to Section 7 of the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock,
as filed by the Company with the Delaware Secretary of State on April 30, 2016 (the “Series C Certificate of Designation”),
in connection with a New Issuance Price (as defined in the Series C Certificate of Designation) at any time prior to the Expiration
Date, the Conversion Price (as defined in the Series C Certificate of Designation) of the Series C Preferred Stock in effect at
such time shall immediately be reduced to such New Issuance Price (hereinafter referred to as the “Adjustment of Conversion
Price”);

 

    	 	 	 

     

    

 

WHEREAS, Section
1.2(b) of the Registration Rights Agreement entitles each Subscriber party thereto to receive a payment in the amount of 1% per
month of such Subscriber’s investment in the 2015 Financing for every thirty (30) day period (up to a maximum of 6%) in which
the Company has failed to, among other things, have a registration statement covering the Registrable Securities (as defined in
the Registration Rights Agreement) declared effective by the U.S. Securities and Exchange Commission by the Effective Date (as
defined in the Registration Rights Agreement) (the “Penalty Payment”);

 

WHEREAS, the parties
have conditioned a Bridge Financing on, among other things, the Company receiving a waiver from the requisite investors needed
to provide such waiver under the Subscription Agreement, Investor Warrants, Placement Agent Warrants, Series C Certificate of Designation,
and the Registration Rights Agreement with regard to (i) the Price Protection Provision; (ii) the Adjustment of the Exercise Price;
(iii) the Adjustment of Conversion Price; and (iv) the Penalty Payment;

 

WHEREAS, in connection
with a potential Bridge Financing, each of the undersigned holders of Series C Preferred Stock, consisting of all of the holders,
desire to set forth their agreement to waive the Adjustment of Conversion Price;

 

WHEREAS, pursuant
to Section 9(i) of the Subscription Agreement, any term of the Subscription Agreement may be modified or waived with the written
consent of the Company and the holders of at least 60% of the Units sold in the Offering (as defined in the Subscription Agreement),
including the Lead Investors (the “Subscription Agreement Requisite Amount”);

 

WHEREAS, pursuant
to Section 3.3 of the Registration Rights Agreement, any term of the Registration Rights Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively) with the written consent of the Company and the holders
of at least 60% of the Registrable Securities then outstanding, including the Lead Investors (the “Registration Rights
Agreement Requisite Amount”);

 

WHEREAS, pursuant
to Section 6(l) of the Investor Warrants, any term of the Investor Warrants may be modified or waived with the written consent
of the Company and the holders of at least 60% of the then outstanding Investor Warrants, including the Lead Investors (the “Investor
Warrant Requisite Amount”);

 

WHEREAS, pursuant
to Section 6(l) of the Placement Agent Warrants, any term of a Placement Agent Warrant may be modified or waived with the written
consent of the Company and such holder; and

 

WHEREAS, as an inducement
for investors to enter into a Bridge Financing, the Company desires to extend the applicability of the Price Protection Provision,
the Adjustment of the Exercise Price and the Adjustment of Conversion Price to any Bridge Financing transaction occurring during
calendar year 2017.

 

    	 	2	 

     

    

 

NOW,
THEREFORE, in consideration of the foregoing, the premises set forth herein, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.          Subscription
Agreement Modification. The Subscription Agreement Requisite Amount hereby agree that the Subscription Agreement shall
be modified such that, upon the occurrence of a Lower Price Issuance occurring prior to the Expiration Date, the Company shall
only issue the Subscribers additional shares of Common Stock at a price per share equal to $0.40. For the avoidance of doubt, it
is the understanding of the Subscription Agreement Requisite Amount and the Company that no Investor Warrants shall be issued in
connection with the foregoing as a result of a Bridge Financing. In addition, pursuant to the terms of the Subscription Agreement,
upon the issuance of additional shares of Common Stock to the Subscribers in connection with a Bridge Financing, the Price Protection
Provision shall be of no further force or effect.

 

2.          Warrant
Exercise Price Adjustment Waiver. The undersigned investors, which constitute (i) the Investor Warrant Requisite Amount
and (ii) all of the holders of the Placement Agent Warrants, hereby agree that the Adjustment of the Exercise Price shall be waived
and of no force or effect in connection with, and as a result of, a Bridge Financing occurring prior to the Expiration Date. Additionally,
(i) the Investor Warrant Requisite Amount and (ii) all of the holders of the Placement Agent Warrants, hereby set forth their consent
that, upon an adjustment pursuant hereto, the Adjustment of the Exercise Price of both the Investor Warrants and Placement Agent
Warrants shall thereafter be of no further force or effect.

 

3.          Registration
Rights Penalty Payment Waiver. As of the Effective Date, the undersigned investors in the 2015 Financing, which constitute
the Registration Rights Agreement Requisite Amount, hereby waive (i) all of their rights related to the Penalty Payment and (ii)
the requirement to register the Registrable Securities pursuant to the Registration Rights Agreement.

 

4.          Series
C Conversion Price Adjustment Waiver. In connection with a Bridge Financing occurring prior to the Expiration Date,
the undersigned holders of Series C Preferred Stock, constituting all of the holders, hereby waive all of their rights
related to the Conversion Price Adjustment.

 

5.          Extension
of Expiration Date. Notwithstanding the Expiration Date, the Company and the undersigned hereby agree that the Price Protection
Provision, the Adjustment of the Exercise Price and the Adjustment of Conversion Price shall remain in effect and apply to all
Subscribers in the 2015 Financing in accordance with the terms provided in this Agreement, at a price per share equal to $0.40,
in connection with a Bridge Financing transaction occurring during calendar year 2017 (the “Extension”). For
the avoidance of doubt, the Extension shall also apply to the Placement Agent Warrants.

 

6.          Governing
Law. This Agreement and related agreements, instruments, and documents shall be governed by, and construed in accordance
with, the laws of the State of New York, without regard to the conflicts of laws principles thereof.

 

7.          Entire
Agreement. This Agreement constitutes the complete understanding of the parties hereto and the Company regarding the subject
matter hereof and supersedes any and all other agreements, either oral or in writing, between the parties with respect to the subject
matter hereof, and no other statement or promise relating to the subject matter hereof that is not contained herein, shall be valid
or binding.

 

[Signature
Page Follows]

 

    	 	3	 

     

    

 

IN WITNESS WHEREOF,
the undersigned, intending to be legally bound, has duly executed this Consent and Waiver Agreement as of the Effective Date.

 

	 	COMPANY:
	 	 
	 	SEVION THERAPEUTICS, INC.
	 	 
	 	By:	 
	 	Name: David Rector
	 	Title: Chief Executive Officer

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF,
the undersigned, intending to be legally bound, has duly executed this Consent and Waiver Agreement as of the Effective Date.

 

	 	LEAD INVESTOR:
	 	 
	 	
	 	 	 
	 	By:	 

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF,
the undersigned, intending to be legally bound, has duly executed this Consent and Waiver Agreement as of the Effective Date for
each share of Common Stock, Series C Preferred Stock, Investor Warrant, and Placement Agent Warrant owned by the undersigned, as
applicable.

 

	 	INVESTOR NAME:	 

 

	 	By:	 

 

	 	Name of Signatory: 	 

 

	 	Title:Exhibit 10.2

 

PREFERRED STOCK EXCHANGE AGREEMENT

 

This PREFERRED STOCK
EXCHANGE AGREEMENT (this “Agreement”) is dated as of February 15, 2017, by and between Sevion Therapeutics,
Inc., a Delaware corporation (the “Company”), and the holder listed on the signature page hereto (the “Holder”).

 

WHEREAS, the Holder
owns shares of the Company’s 10% Series A Convertible Preferred Stock, par value $0.01 per share (the “Preferred
Stock”), which may be converted into shares of the Company’s common stock, par value $0.01 per share (the “Common
Stock”);

 

WHEREAS, the number
of shares of Preferred Stock held by the Holder is set forth on the signature page attached hereto (the “Preferred Shares”);

 

WHEREAS, in order
to improve the capital structure of the Company, the Company and the Holder desire to enter into this Agreement, pursuant to which,
among other things, the Company and the Holder shall exchange the Preferred Stock for the number of shares of Common Stock, as
calculated below (the “Exchange”);

 

WHEREAS, following
the Exchange, the Preferred Stock shall be automatically cancelled and terminated and the Holder shall have no further rights pursuant
to the Preferred Stock; and

 

WHEREAS, the Exchange
is being made in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended
(the “Securities Act”).

 

NOW, THEREFORE,
in consideration of the premises and mutual covenants herein below, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.          The
Exchange. At the Closing (as defined below), the Company and the Holder shall, pursuant to Section 3(a)(9) of the Securities
Act, convert the Preferred Stock into Common Stock, as follows:

 

1.1.          Closing.
The Exchange shall occur remotely via the exchange of signatures on such later date as determined by the Company (the “Closing”).
The Holder understands that this Agreement is not binding on the Company until the Company accepts it, which acceptance is in the
Company’s sole discretion, by executing this Agreement where indicated.

 

1.2.          Exchange
Shares. The Holder shall receive such number of shares of Common Stock equal the product of (x) the number of Preferred Shares
multiplied by (y) 1,000, divided by (z) 0.25 (the “Exchange Shares”).

 

(a)          No
fractional shares or scrip representing fractional shares shall be issued upon the Exchange. As to any fraction of a share which
the Holder would otherwise be entitled pursuant to the Exchange, the Company shall at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by $0.25 or round up to the next whole share.

 

    	 	 	 

     

    

 

1.3.          Consideration.
At the Closing, the Exchange Shares shall be issued to the Holder in exchange for the Preferred Stock without the payment of any
other consideration by the Holder that would not be consistent with the application of Section 3(a)(9) of the Securities Act to
the issuance of the Exchange Shares. The Holder hereby agrees that, upon and subject to the Closing, all of the Company’s
obligations under the terms and conditions of the Preferred Stock shall be automatically terminated and cancelled in full without
any further action required, and that this Section 1.3 shall constitute an instrument of termination and cancellation of such Preferred
Stock.

 

1.4.          Delivery.
In the Exchange, the Company shall, at the Closing, deliver the Exchange Shares to the Holder (in electronic or certificated form
as determined by the Company and its transfer agent). The Holder shall deliver or cause to be delivered to the Company (or its
designee), within five (5) Trading Days after the Closing, the original Preferred Stock certificate. For the avoidance of doubt,
as of the Closing all of the Holder’s rights under the terms and conditions of the Preferred Stock shall be extinguished.

 

1.5.          Other
Documents. The Company and the Holder shall execute and/or deliver such other documents and agreements as are reasonably necessary
to effectuate the Exchange pursuant to the terms of this Agreement.

 

2.          Representations
and Warranties.

 

2.1.          Holder
Representations and Warranties. The Holder hereby represents and warrants to the Company:

 

(a)          The
Holder is either an individual or an entity validly existing and in good standing under the laws of the jurisdiction of its organization.

 

(b)          This
Agreement has been duly authorized, validly executed and delivered by the Holder and is a valid and binding agreement and obligation
of the Holder enforceable against the Holder in accordance with its terms, subject to limitations on enforcement by general principles
of equity and by bankruptcy or other laws affecting the enforcement of creditors’ rights generally, and the Holder has full
power and authority to execute and deliver this Agreement and the other agreements and documents referred to in Section 1.5 and
to perform its obligations hereunder and thereunder.

 

(c)          The
Holder understands that the Exchange Shares are being offered, sold, issued and delivered to it in reliance upon specific provisions
of federal and applicable state securities laws, and that the Company is relying upon the truth and accuracy of the representations,
warranties, agreements, acknowledgments and understandings of the Holder set forth herein for purposes of qualifying for exemptions
from registration under the Securities Act and applicable state securities laws.

 

(d)          The
Holder is not acquiring the Exchange Shares as a result of any advertisement, article, notice or other communication regarding
the Exchange Shares published in any newspaper, magazine or similar media or broadcast over television or radio or presented at
any seminar or any other general advertisement.

 

    	 	2	 

     

    

 

(e)          The
Holder, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Exchange Shares, and has so
evaluated the merits and risks of such investment. The Holder is able to bear the economic risk of an investment in the Exchange
Shares and, at the present time, is able to afford a complete loss of such investment.

 

(f)          The
Holder acknowledges that the offer, sale, issuance and delivery of the Exchange Shares to it is intended to be exempt from registration
under the Securities Act, by virtue of Section 3(a)(9) thereof. The Holder understands that the Exchange Shares may be sold or
transferred only in compliance with all federal and applicable state securities laws.

 

(g)          The
Holder understands that the Exchange Shares are “restricted securities” and have not been registered under the Securities
Act or any applicable state securities law and the Holder is acquiring the Exchange Shares as principal for its own account and
not with a view to or for distributing or reselling such Exchange Shares or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Exchange Shares in violation of the
Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other
persons to distribute or regarding the distribution of such Exchange Shares in violation of the Securities Act or any applicable
state securities law (this representation and warranty not limiting such Holder’s right to sell the Securities in compliance
with applicable federal and state securities laws). Such Holder is acquiring the Exchange Shares hereunder in the ordinary course
of its business.

 

(h)          The
Holder owns and holds, beneficially and of record, the entire right, title, and interest in and to the Preferred Shares free and
clear of all rights and Encumbrances (as defined below). The Holder has full power and authority to transfer and dispose of the
Preferred Shares to the Company free and clear of any right or Encumbrance. Other than the transactions contemplated by this Agreement,
there is no outstanding vote, plan, pending proposal, or other right of any person to acquire all or any of the Preferred Shares.
As used herein, “Encumbrances” shall mean any security or other property interest or right, claim, lien, pledge,
option, charge, security interest, contingent or conditional sale, or other title claim or retention agreement, interest or other
right or claim of third parties, whether perfected or not perfected, voluntarily incurred or arising by operation of law, and including
any agreement (other than this Agreement) to grant or submit to any of the foregoing in the future. The Preferred Shares constitute
all of the Preferred Stock owned or held of record or beneficially owned or held by the Holder.

 

    	 	3	 

     

    

 

2.2.          Company
Representations and Warranties. The Company hereby represents and warrants to the Holder:

 

(a)          The
Company has been duly incorporated and is validly existing and in good standing under the laws of the State of Delaware, with full
corporate power and authority to own, lease and operate its properties and to conduct its business as currently conducted, and
is duly registered and qualified to conduct its business and is in good standing in each jurisdiction or place where the nature
of its properties or the conduct of its business requires such registration or qualification, except where the failure to so register
or qualify would not have a Material Adverse Effect. For purposes of this Agreement, “Material Adverse Effect”
shall mean any material adverse effect on the business, operations, properties, or financial condition of the Company and its subsidiaries
and/or any condition, circumstance, or situation that would prohibit or otherwise materially interfere with the ability of the
Company to perform any of its obligations under this Agreement.

 

(b)          The
Exchange Shares have been duly authorized by all necessary corporate action, and, when issued and delivered in accordance with
the terms hereof, the Exchange Shares shall be validly issued and outstanding, fully paid and nonassessable, free and clear of
all liens, encumbrances and rights of refusal of any kind.

 

(c)          This
Agreement has been duly authorized, validly executed and delivered on behalf of the Company and is a valid and binding agreement
and obligation of the Company enforceable against the Company in accordance with its terms, subject to limitations on enforcement
by general principles of equity and by bankruptcy or other laws affecting the enforcement of creditors’ rights generally,
and the Company has full power and authority to execute and deliver this Agreement and the other agreements and documents contemplated
hereby and to perform its obligations hereunder and thereunder.

 

(d)          The
Company represents that it has not paid, and shall not pay, any commissions or other remuneration, directly or indirectly, to any
third party for the solicitation of the Exchange pursuant to this Agreement. Other than the exchange of the Preferred Stock, the
Company has not received and will not receive any consideration from the Holder for the Exchange Shares.

 

(e)          The
Company has not, nor has any person acting on its behalf, directly or indirectly made any offers or sales of any security or solicited
any offers to buy any security under circumstances that would cause the Exchange and the issuance of the Exchange Shares pursuant
to this Agreement to be integrated with prior offerings by the Company for purposes of the Securities Act which would prevent the
Company from delivering the Exchange Shares to the Holder pursuant to Section 3(a)(9) of the Securities Act, nor will the Company
take any action or steps that would cause the Exchange, issuance and delivery of the Exchange Shares to be integrated with other
offerings to the effect that the delivery of the Exchange Shares to the Holder would be seen not to be exempt pursuant to Section
3(a)(9) of the Securities Act.

 

(f)          For
the purposes of Rule 144 of the Securities Act, the Company acknowledges that the holding period of the Exchange Shares may be
tacked onto the holding period of the Preferred Shares pursuant to applicable rules, regulations and interpretations, and the Company
agrees not to take a position contrary to this Section 2.2(f).

 

    	 	4	 

     

    

 

(g)          The
Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none
of the terms offered to any person with respect to any consent, release, amendment, settlement or waiver relating to the terms,
conditions and transactions contemplated hereby (each a “Settlement Document”), is or will be more favorable
to such person than those of the Holder and this Agreement. If, and whenever on or after the date hereof, the Company enters into
a Settlement Document, then (i) the Company shall provide notice thereof to the Holder immediately following the occurrence thereof
and (ii) the terms and conditions of this Agreement shall be, without any further action by the Holder or the Company, automatically
amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more
favorable terms and/or conditions (as the case may be), provided that upon written notice to the Company at any time the Holder
may elect not to accept the benefit of any such amended or modified term or condition, in which event the term or condition contained
in this Agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such
amendment or modification never occurred with respect to the Holder. The provisions of this Section 2.2(g) shall apply similarly
and equally to each Settlement Document.

 

(h)          The
execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated
hereby (including, without limitation, the issuance of the Exchange Shares) will not (i) result in a violation of the certificate
of incorporation or bylaws of the Company or (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture or instrument to which the Company or any of its subsidiaries is a party, or (iii)
result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state securities
laws and regulations and the rules and regulations by which any property or asset of the Company or any of its subsidiaries is
bound or affected).

 

3.          Miscellaneous.

 

3.1.          Entire
Agreement. This Agreement constitutes the entire agreement, and supersedes all other prior and contemporaneous agreements and
understandings, both oral and written, between the Holder and the Company with respect to the subject matter hereof.

 

3.2.          Amendment.
This Agreement may only be amended with the written consent of the Holder and the Company.

 

3.3.          Successors.
All the covenants and provisions of this Agreement by or for the benefit of the Holder or the Company shall bind and inure to the
benefit of their respective successors and assigns.

 

3.4.          Applicable
Law; Consent to Jurisdiction. The validity, interpretation and performance of this Agreement shall be governed in all respects
by the laws of the State of Delaware, without giving effect to conflicts of law principles that would result in the application
of the substantive laws of another jurisdiction. Each of the parties hereby agrees that any action, proceeding or claim against
it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of Delaware
or the United States District Court for the District of Delaware, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive. Each party hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum.

 

    	 	5	 

     

    

 

3.5.          Counterparts.
This Agreement may be executed in original or facsimile counterparts, each of such counterparts shall for all purposes be deemed
to be an original, and all of such counterparts shall together constitute but one and the same instrument.

 

3.6.          Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be
ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

3.7.          No
Commissions. Neither the Company nor the Holder has paid or given, or will pay or give, to any person, any commission, fee
or other remuneration, directly or indirectly, in connection with the transactions contemplated by this Agreement.

 

* * * * * * *

 

    	 	6	 

     

    

 

IN WITNESS WHEREOF,
this Preferred Stock Exchange Agreement has been duly executed by the undersigned as of the date first written above.

 

	 	HOLDER:	 
	 	 	 
	 	 	 
	 	 	 
	 	By:	 	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	PREFERRED SHARES:	 
	 	 	 
	 	 	 
	 	 	 	 

 

ACKNOWLEDGEMENT

 

This Preferred Stock Exchange Agreement is hereby
accepted upon the terms and conditions set forth above.

 

	 	SEVION THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	Name:	David Rector
	 	Title:	President and CEO
	 	 	 
	 	Dated:	 

 

[Signature
Page to the Preferred Stock Exchange Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]